RAC Product Development & Registration 3 — Questions and Answers
Question 1: What is the primary regulatory distinction between a drug product's 'indication' and its 'intended use' in labeling?
- Indication refers to the disease state targeted; intended use encompasses the broader population and clinical setting described in labeling (Correct answer)
- Intended use applies only to devices, not drugs
- Indication is determined by the manufacturer, while intended use is set exclusively by FDA
- They are legally interchangeable terms under 21 CFR
Correct answer: Indication refers to the disease state targeted; intended use encompasses the broader population and clinical setting described in labeling
An indication specifies the disease or condition the drug treats, while intended use in labeling describes the full clinical context including population, setting, and purpose.
Question 2: Under the Common Technical Document (CTD) structure, Module 4 contains which type of information?
- Clinical study reports
- Nonclinical study reports (Correct answer)
- Quality/chemistry, manufacturing, and controls data
- Administrative and regional information
Correct answer: Nonclinical study reports
Module 4 of the CTD contains nonclinical (pharmacology and toxicology) study reports supporting safety evaluation of the drug.
Question 3: A company wants to make a manufacturing change to an approved NDA product that has 'substantial potential' to adversely affect drug identity, strength, quality, purity, or potency. What submission is required?
- Annual Report
- Changes Being Effected (CBE-30) supplement
- Prior Approval Supplement (PAS) (Correct answer)
- Notification letter only
Correct answer: Prior Approval Supplement (PAS)
Changes with substantial potential to affect product quality require a Prior Approval Supplement, which must be approved by FDA before the change is implemented.
Question 4: Which clinical trial phase is primarily designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a new drug in a small number of healthy volunteers or patients?
- Phase 1 (Correct answer)
- Phase 2a
- Phase 2b
- Phase 3
Correct answer: Phase 1
Phase 1 trials are first-in-human studies focused on safety, tolerability, PK/PD, and dose range finding in small groups (typically 20–100 subjects).
Question 5: What is the role of a Reference Listed Drug (RLD) in the ANDA (generic drug) approval process?
- It serves as the benchmark to which the generic applicant must demonstrate bioequivalence (Correct answer)
- It is the first generic product approved for a given indication
- It is the FDA-designated comparator used only in pediatric studies
- It replaces the innovator drug once the patent expires
Correct answer: It serves as the benchmark to which the generic applicant must demonstrate bioequivalence
The RLD is the approved brand-name drug to which a generic applicant must demonstrate bioequivalence in an ANDA submission.
Question 6: Under ICH E6(R2) Good Clinical Practice guidelines, what is the sponsor's primary responsibility regarding an Investigational Medicinal Product (IMP)?
- Conducting all site monitoring visits personally
- Ensuring the IMP is manufactured, handled, and stored in accordance with applicable GMP and used in accordance with the approved protocol (Correct answer)
- Designing the statistical analysis plan for the trial
- Recruiting and enrolling all study subjects
Correct answer: Ensuring the IMP is manufactured, handled, and stored in accordance with applicable GMP and used in accordance with the approved protocol
ICH E6(R2) places responsibility on the sponsor for ensuring proper GMP manufacture, appropriate handling/storage, and protocol-compliant use of the IMP.
Question 7: What triggers the requirement for a Risk Evaluation and Mitigation Strategy (REMS) for an NDA or BLA?
- Any drug that requires a prescription
- FDA determines that a REMS is necessary to ensure the benefits of the drug outweigh its risks given a serious safety concern (Correct answer)
- All drugs with a black box warning automatically require a REMS
- The sponsor voluntarily requests enhanced safety monitoring
Correct answer: FDA determines that a REMS is necessary to ensure the benefits of the drug outweigh its risks given a serious safety concern
REMS is required when FDA determines that additional risk management beyond labeling is necessary because of a serious safety concern specific to that drug.
RAC Product Development & Registration 3
What is the primary regulatory distinction between a drug product's 'indication' and its 'intended use' in labeling?